Apixaban for Extended Treatment of Provoked Venous Thromboembolism
New England Journal of Medicine · 25.09.2025 · 393 (12) · 1166-1176
DOI: 10.1056/nejmoa2509426 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift New England Journal of Medicine, erschienen am 25.09.2025. Verfasst von Gregory Piazza und 19 weiteren Autor:innen. Beteiligte Einrichtung: Thrombosis Research Group, Brigham and Women's Hospital-Harvard Medical School, Boston. Hauptthemen laut MEDLINE: Anticoagulants, Factor Xa Inhibitors, Pyrazoles, Pyridones. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Bristol-Myers Squibb Foundation, Bristol Myers Squibb Foundation.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
BACKGROUND: The appropriate duration of anticoagulation for venous thromboembolism (VTE) in patients who have a transient provoking factor (e.g., surgery, trauma, or immobility) and concomitant enduring risk factors is uncertain. METHODS: In this single-center, double-blind, randomized trial, adults with VTE after the occurrence of a transient provoking factor who had at least one enduring risk factor and had completed at least 3 months of anticoagulation were assigned to receive oral apixaban (at a dose of 2.5 mg twice daily) or placebo for 12 months. The primary efficacy outcome was the first symptomatic recurrent VTE. The primary safety outcome was the first episode of major bleeding according to the criteria of the International Society on Thrombosis and Hemostasis. RESULTS: A total of 600 patients underwent randomization (mean age, 59.5 years; female sex, 57.0%; non-White race, 19.2%). The trial population had a broad range of provoking factors and enduring risk factors. Symptomatic recurrent VTE occurred in 4 of the 300 patients (1.3%) in the apixaban group and in 30 of the 300 patients (10.0%) in the placebo group (hazard ratio, 0.13; 95% confidence interval [CI], 0.04 to 0.36; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Thrombosis Research Group, Brigham and Women's Hospital-Harvard Medical School, Boston.
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital-Harvard Medical School, Boston.
- Yale New Haven Hospital, Yale Center for Outcomes Research and Evaluation, New Haven, CT.
- Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh.
- Department of Pharmacy, Brigham and Women's Hospital-Harvard Medical School, Boston.
- Division of Cardiology, Beth Israel Deaconess Medical Center, Boston.
ORCID-Profile: Gregory Piazza, Darsiya Krishnathasan
Förderung
- Bristol-Myers Squibb Foundation
- Bristol Myers Squibb Foundation
Zitieren
APA
Piazza, G., Bikdeli, B., Pandey, A. K., Krishnathasan, D., Khairani, C. D., Bejjani, A., Morrison, R. H., Hogan, H., Rashedi, S., Pfeferman, M., Lou, J., Fanikos, J., Porio, N., Rosenbaum, L., Sobieszczyk, P., Lan, Z., Gerhard-Herman, M., Campia, U., Goldhaber, S. Z., & HI-PRO Trial Investigators (2025). Apixaban for Extended Treatment of Provoked Venous Thromboembolism. New England Journal of Medicine, 393(12), 1166-1176. https://doi.org/10.1056/nejmoa2509426
Vancouver
Piazza G, Bikdeli B, Pandey AK, Krishnathasan D, Khairani CD, Bejjani A, et al. Apixaban for Extended Treatment of Provoked Venous Thromboembolism. New England Journal of Medicine. 2025;393(12):1166-1176. doi:10.1056/nejmoa2509426
BibTeX
@article{Piazza2025,
author = {Piazza, Gregory and Bikdeli, Behnood and Pandey, Arvind K and Krishnathasan, Darsiya and Khairani, Candrika D and Bejjani, Antoine and Morrison, Ruth H and Hogan, Heather and Rashedi, Sina and Pfeferman, Mariana and Lou, Junyang and Fanikos, John and Porio, Nicole and Rosenbaum, Lisa and Sobieszczyk, Piotr and Lan, Zhou and Gerhard-Herman, Marie and Campia, Umberto and Goldhaber, Samuel Z and HI-PRO Trial Investigators, HI-PRO Trial Investigators},
title = {Apixaban for Extended Treatment of Provoked Venous Thromboembolism},
journal = {New England Journal of Medicine},
year = {2025},
volume = {393},
number = {12},
pages = {1166--1176},
doi = {10.1056/nejmoa2509426}
}
EUVIMED